=Merck (MRK) reported earnings on Tue 29 Oct 19 (b/o)

Merck beats by $0.28, beats on revs; raises FY19 EPS and rev above consensus

Reports Q3 (Sep) earnings of $1.51 per share, excluding non-recurring items, $0.28 better than the S&P Capital IQ Consensus of $1.23; revenues rose 14.9% year/year to $12.4 bln vs the $11.59 bln S&P Capital IQ Consensus. 

KEYTRUDA Sales Grew 62% to $3.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 64%

Human Health Vaccines Sales Grew 17% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 18%

Co issues upside guidance for FY19, raises EPS of $5.12-5.17 from $4.84-4.94, excluding non-recurring items, vs. $4.97 S&P Capital IQ Consensus; raises FY19 revs to $46.5-47.0 bln from $45.2-46.2 bln vs. $45.88 bln S&P Capital IQ Consensus.